SelectQuote Reports 7% Revenue Growth Amid Medicare Advantage Shifts
Event summary
- SelectQuote reported Q3 FY2026 revenue of $430.9M, up 7% YoY from $408.2M.
- Net income rose to $40.2M, a 55% increase from $26.0M in the prior-year quarter.
- Adjusted EBITDA increased by 18% YoY to $44.6M.
- Senior segment revenue grew 8% YoY to $182.9M, while Healthcare Services revenue increased 5% YoY to $199.4M.
- SelectRx membership grew by 11% YoY, with average prescriptions shipped per day rising by 14%.
The big picture
SelectQuote's Q3 FY2026 results highlight its ability to deliver consistent profit and cash flow despite market volatility in Medicare Advantage and prescription drugs. The company's strategic focus on operational execution and technology advantages positions it to expand cash flow in the future. The growth in SelectRx membership and pharmacy revenue underscores the value of its differentiated healthcare service model.
What we're watching
- Market Dynamics
- How SelectQuote will navigate ongoing Medicare Advantage and prescription drug market shifts.
- Cash Flow Expansion
- Whether the company can sustain its receivables growth and improve cash flow in the coming years.
- Operational Efficiency
- The pace at which SelectQuote can leverage its technology and agent network to drive further profitability.
Related topics